Related Experiment Video

Updated: Sep 3, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.7K

The story of EGFR: from signaling pathways to a potent anticancer target

Saloni Ramani1, Sayalee Samant1, Sonal M Manohar1

  • 1Department of Biological Sciences, Sunandan Divatia School of Science, NMIMS (Deemed-to-Be) University, Vile Parle (West), Mumbai, 400056, India.

Future Medicinal Chemistry
|July 26, 2022
PubMed

Insights

Epidermal Growth Factor Receptor (EGFR) signaling drives cancer growth. Inhibiting EGFR offers a promising anticancer strategy, but resistance mechanisms limit its effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Epidermal Growth Factor Receptor (EGFR) is crucial for cell growth, survival, and differentiation.
  • EGFR deregulation is linked to various human cancers, making it a key therapeutic target.
  • EGFR signaling pathways are complex and activated in numerous malignancies.

Purpose of the Study:

  • To review the cellular signaling pathways activated by EGFR.
  • To highlight current therapeutic strategies targeting aberrant EGFR signaling in cancer.
  • To discuss the mechanisms of resistance to EGFR-targeted therapies.

Main Methods:

  • Literature review of EGFR signaling pathways.
  • Analysis of therapeutic strategies targeting EGFR.
  • Examination of resistance mechanisms to EGFR inhibitors.

Main Results:

  • EGFR inhibition via tyrosine kinase inhibitors and monoclonal antibodies shows efficacy against cancer cells.
  • EGFR inhibitors are a superior treatment to chemotherapy for advanced EGFR-driven non-small-cell lung cancer.
  • Both de novo and acquired resistance to EGFR inhibitors pose significant clinical challenges.

Conclusions:

  • Targeting EGFR signaling is a vital strategy in cancer therapy.
  • Understanding EGFR-driven pathways and resistance mechanisms is crucial for improving treatment outcomes.
  • Further research into overcoming resistance is necessary to maximize the clinical benefit of EGFR inhibitors.
Keywords:
EGFRdrug resistancemonoclonal antibodiessignaling pathwaystyrosine kinase inhibitors

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K